Abstract
A common target for therapies against human immuno-deficiency virus type 1 (HIV-1) is the viral reverse transcriptase (RT). Treatment with the widely used nucleoside analog (-)-2', 3'-deoxy-3'-thiacytidine (3TC) leads to the development of resistance-conferring mutations at residue M184 within the YMDD motif of RT. First, variants of HIV with the M184I substitution appear transiently, followed by viruses containing the M184V substitution, which persist and become the dominant variant for the duration of therapy. In the three-dimensional crystal structure of HIV-1 RT complexed with double-stranded DNA, the M184 residue lies in the vicinity of the primer terminus, near the incoming dNTP substrate. Recent studies have shown that 3TC resistance mutations, including M184I, increase the nucleotide insertion and mispair extension fidelity. Therefore, we have examined the effects of the M184I mutation on the overall polymerase fidelity of HIV-1 RT via an M13-based forward mutation assay. We found the overall error rate of the M184I variant of HIV-1 RT to be 1.7 x 10(-5) per nucleotide. This represents a 4-fold increase in fidelity over wild-type HIV-1Hxb2RT (7.0 x 10(-5) per nucleotide) and a 2.5-fold increase in fidelity over the M184V variant (4.3 x 10(-5) per nucleotide). Of the nucleoside analog resistance mutations studied using the forward assay, the M184I variant has shown the greatest increase in fidelity observed to date. Interestingly, the M184I variant RT displays significantly altered error specificity, both in terms of error rate at specific sites and in the overall ratio of substitution to frameshift mutations in the entire target.
Full Text
The Full Text of this article is available as a PDF (211.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Back N. K., Nijhuis M., Keulen W., Boucher C. A., Oude Essink B. O., van Kuilenburg A. B., van Gennip A. H., Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 1996 Aug 1;15(15):4040–4049. [PMC free article] [PubMed] [Google Scholar]
- Beard W. A., Minnick D. T., Wade C. L., Prasad R., Won R. L., Kumar A., Kunkel T. A., Wilson S. H. Role of the "helix clamp" in HIV-1 reverse transcriptase catalytic cycling as revealed by alanine-scanning mutagenesis. J Biol Chem. 1996 May 24;271(21):12213–12220. doi: 10.1074/jbc.271.21.12213. [DOI] [PubMed] [Google Scholar]
- Bebenek K., Abbotts J., Roberts J. D., Wilson S. H., Kunkel T. A. Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J Biol Chem. 1989 Oct 5;264(28):16948–16956. [PubMed] [Google Scholar]
- Bebenek K., Abbotts J., Wilson S. H., Kunkel T. A. Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J Biol Chem. 1993 May 15;268(14):10324–10334. [PubMed] [Google Scholar]
- Bebenek K., Beard W. A., Casas-Finet J. R., Kim H. R., Darden T. A., Wilson S. H., Kunkel T. A. Reduced frameshift fidelity and processivity of HIV-1 reverse transcriptase mutants containing alanine substitutions in helix H of the thumb subdomain. J Biol Chem. 1995 Aug 18;270(33):19516–19523. doi: 10.1074/jbc.270.33.19516. [DOI] [PubMed] [Google Scholar]
- Bebenek K., Kunkel T. A. Analyzing fidelity of DNA polymerases. Methods Enzymol. 1995;262:217–232. doi: 10.1016/0076-6879(95)62020-6. [DOI] [PubMed] [Google Scholar]
- Chao S. F., Chan V. L., Juranka P., Kaplan A. H., Swanstrom R., Hutchison C. A., 3rd Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res. 1995 Mar 11;23(5):803–810. doi: 10.1093/nar/23.5.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
- Drosopoulos W. C., Prasad V. R. Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro. J Virol. 1998 May;72(5):4224–4230. doi: 10.1128/jvi.72.5.4224-4230.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Drosopoulos W. C., Prasad V. R. Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1996 Jul;70(7):4834–4838. doi: 10.1128/jvi.70.7.4834-4838.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eckert K. A., Kunkel T. A. Fidelity of DNA synthesis catalyzed by human DNA polymerase alpha and HIV-1 reverse transcriptase: effect of reaction pH. Nucleic Acids Res. 1993 Nov 11;21(22):5212–5220. doi: 10.1093/nar/21.22.5212. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gao Q., Gu Z. X., Parniak M. A., Li X. G., Wainberg M. A. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol. 1992 Jan;66(1):12–19. doi: 10.1128/jvi.66.1.12-19.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gao Q., Gu Z., Hiscott J., Dionne G., Wainberg M. A. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1993 Jan;37(1):130–133. doi: 10.1128/aac.37.1.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hsu M., Inouye P., Rezende L., Richard N., Li Z., Prasad V. R., Wainberg M. A. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res. 1997 Nov 15;25(22):4532–4536. doi: 10.1093/nar/25.22.4532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jacobo-Molina A., Ding J., Nanni R. G., Clark A. D., Jr, Lu X., Tantillo C., Williams R. L., Kamer G., Ferris A. L., Clark P. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6320–6324. doi: 10.1073/pnas.90.13.6320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jaju M., Beard W. A., Wilson S. H. Human immunodeficiency virus type 1 reverse transcriptase. 3'-Azidodeoxythymidine 5'-triphosphate inhibition indicates two-step binding for template-primer. J Biol Chem. 1995 Apr 28;270(17):9740–9747. doi: 10.1074/jbc.270.17.9740. [DOI] [PubMed] [Google Scholar]
- Keulen W., Back N. K., van Wijk A., Boucher C. A., Berkhout B. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1997 Apr;71(4):3346–3350. doi: 10.1128/jvi.71.4.3346-3350.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kew Y., Olsen L. R., Japour A. J., Prasad V. R. Insertions into the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase reveal a role for fingers subdomain in processive polymerization. J Biol Chem. 1998 Mar 27;273(13):7529–7537. doi: 10.1074/jbc.273.13.7529. [DOI] [PubMed] [Google Scholar]
- Larder B. A., Kemp S. D., Harrigan P. R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995 Aug 4;269(5224):696–699. doi: 10.1126/science.7542804. [DOI] [PubMed] [Google Scholar]
- Mansky L. M., Temin H. M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995 Aug;69(8):5087–5094. doi: 10.1128/jvi.69.8.5087-5094.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mansky L. M. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology. 1996 Aug 15;222(2):391–400. doi: 10.1006/viro.1996.0436. [DOI] [PubMed] [Google Scholar]
- Oude Essink B. B., Back N. K., Berkhout B. Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Res. 1997 Aug 15;25(16):3212–3217. doi: 10.1093/nar/25.16.3212. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pandey V. N., Kaushik N., Rege N., Sarafianos S. G., Yadav P. N., Modak M. J. Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry. 1996 Feb 20;35(7):2168–2179. doi: 10.1021/bi9516642. [DOI] [PubMed] [Google Scholar]
- Rezende L. F., Curr K., Ueno T., Mitsuya H., Prasad V. R. The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity. J Virol. 1998 Apr;72(4):2890–2895. doi: 10.1128/jvi.72.4.2890-2895.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Richman D. D. HIV drug resistance. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1065–1071. doi: 10.1089/aid.1992.8.1065. [DOI] [PubMed] [Google Scholar]
- Roberts J. D., Bebenek K., Kunkel T. A. The accuracy of reverse transcriptase from HIV-1. Science. 1988 Nov 25;242(4882):1171–1173. doi: 10.1126/science.2460925. [DOI] [PubMed] [Google Scholar]
- Roberts J. D., Preston B. D., Johnston L. A., Soni A., Loeb L. A., Kunkel T. A. Fidelity of two retroviral reverse transcriptases during DNA-dependent DNA synthesis in vitro. Mol Cell Biol. 1989 Feb;9(2):469–476. doi: 10.1128/mcb.9.2.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rubinek T., Bakhanashvili M., Taube R., Avidan O., Hizi A. The fidelity of 3' misinsertion and mispair extension during DNA synthesis exhibited by two drug-resistant mutants of the reverse transcriptase of human immunodeficiency virus type 1 with Leu74-->Val and Glu89-->Gly. Eur J Biochem. 1997 Jul 1;247(1):238–247. doi: 10.1111/j.1432-1033.1997.00238.x. [DOI] [PubMed] [Google Scholar]
- Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., Danner S. A., Mulder J., Loveday C., Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995 Jun;171(6):1411–1419. doi: 10.1093/infdis/171.6.1411. [DOI] [PubMed] [Google Scholar]
- Tantillo C., Ding J., Jacobo-Molina A., Nanni R. G., Boyer P. L., Hughes S. H., Pauwels R., Andries K., Janssen P. A., Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol. 1994 Oct 28;243(3):369–387. doi: 10.1006/jmbi.1994.1665. [DOI] [PubMed] [Google Scholar]
- Wainberg M. A., Drosopoulos W. C., Salomon H., Hsu M., Borkow G., Parniak M., Gu Z., Song Q., Manne J., Islam S. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 1996 Mar 1;271(5253):1282–1285. doi: 10.1126/science.271.5253.1282. [DOI] [PubMed] [Google Scholar]
- Wainberg M. A., Salomon H., Gu Z., Montaner J. S., Cooley T. P., McCaffrey R., Ruedy J., Hirst H. M., Cammack N., Cameron J. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 1995 Apr;9(4):351–357. [PubMed] [Google Scholar]
- Winters M. A., Shafer R. W., Jellinger R. A., Mamtora G., Gingeras T., Merigan T. C. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother. 1997 Apr;41(4):757–762. doi: 10.1128/aac.41.4.757. [DOI] [PMC free article] [PubMed] [Google Scholar]